{"id":"bay3723113","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FGFR4 is frequently activated in hepatocellular carcinoma through FGF19 autocrine signaling, driving tumor growth and survival. By selectively inhibiting FGFR4 kinase activity, BAY3723113 disrupts this oncogenic pathway. This selective approach aims to minimize off-target effects associated with pan-FGFR inhibitors while maintaining efficacy against FGFR4-dependent tumors.","oneSentence":"BAY3723113 is a selective inhibitor of fibroblast growth factor receptor 4 (FGFR4) that blocks aberrant FGF/FGFR signaling in hepatocellular carcinoma and other cancers.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:37.095Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma (HCC), FGFR4-positive or FGF19-positive"}]},"trialDetails":[{"nctId":"NCT07023341","phase":"PHASE3","title":"A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2025-06-30","conditions":"Obstructive Hypertrophic Cardiomyopathy","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CK-3773274"],"phase":"phase_3","status":"active","brandName":"BAY3723113","genericName":"BAY3723113","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BAY3723113 is a selective inhibitor of fibroblast growth factor receptor 4 (FGFR4) that blocks aberrant FGF/FGFR signaling in hepatocellular carcinoma and other cancers. Used for Hepatocellular carcinoma (HCC), FGFR4-positive or FGF19-positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}